Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.47 |
| ▸ | RAB9A | P51151 | 9/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.40 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.38 |
| ▸ | TP53 | P04637 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31709424 | 0.84 | NPC1 (0.49) | NPC1RAB9AKMT2ASMN1; SMN2TP53 | |
| SCHEMBL12350646 | 0.82 | DDAH1 (0.58) | NPC1RAB9AKMT2ADDAH1SMN1; SMN2 | |
| SCHEMBL31569739 | 0.78 | RAB9A (0.44) | NPC1RAB9AKMT2ASMN1; SMN2TP53 | |
| SCHEMBL8278820 | 0.78 | DDAH1 (0.66) | NPC1RAB9AKMT2ADDAH1SMN1; SMN2 | |
| SCHEMBL11223673 | 0.77 | TUBB4A (0.42) | TSHRLMNA | |
| SCHEMBL12940747 | 0.76 | HSD17B10 (0.67) | NPC1RAB9ASMN1; SMN2ALDH1A1LMNA | |
| SCHEMBL1976712 | 0.76 | TDP1 (0.51) | NPC1RAB9AKMT2ADDAH1SMN1; SMN2 | |
| SCHEMBL13628993 | 0.76 | RAB9A (0.42) | NPC1RAB9AKMT2ADDAH1SMN1; SMN2 | |
| SCHEMBL31570020 | 0.76 | TDP1 (0.51) | NPC1RAB9AKMT2ADDAH1SMN1; SMN2 | |
| SCHEMBL17513343 | 0.76 | CACNA1H (0.50) | NPC1RAB9AKMT2ADDAH1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612211-B2 | Benzimidazole TRPV1 inhibitors | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-11-03 | — | — | US | disclosed |
| US-20080146637-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146637-A1 | BENZIMIDAZOLE TRPV1 INHIBITORS | TRPV1, TRPV2, TRPA1 | NPC1 282/4885RAB9A 3194/4885KMT2A 4261/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.